Loading
A phase 1/2 trial of HY05350 for injection in advanced solid tumours, run by Sichuan Huiyu Pharmaceutical Co., Ltd, now recruiting.
A Phase I/II Study of HY05350 in Mesothelin(MSLN)-Positive Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT07083323 by Sichuan Huiyu Pharmaceutical Co., Ltd, with 262 participants planned, started 2025-07-22 and due to reach its primary completion in 2028-03-31. Interventions recorded: HY05350 for injection.
Shares Sichuan Huiyu Pharmaceutical, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Sichuan Huiyu Pharmaceutical, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Sichuan Huiyu Pharmaceutical, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Sichuan Huiyu Pharmaceutical, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Mesothelin and the tag pipeline.
Shares Mesothelin and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.